Interv Akut Kardiol. 2009;8(3):149-152

Fondaparinux

Ondřej Dostál¹, doc. MUDr. Debora Karetová CSc², MUDr. Lenka Skalická², Jean-Claude Lubanda²

¹ II. interní klinika, VFN, Praha

² II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Fondaparinux is a new drug which belongs to parenteral anticoagulants. The efficacy and safety of this drug were proven in numerous

clinical trials for several indications. Fondaprinux is a synthetic and specific inhibitor of activated factor X in the coagulation cascade.

In comparison to unfractionated heparin (UFH) and low molecular weight heparins (LMWH), fondaparinux does not interact with thrombin.

Its main advantage is the long half time which allows once daily administration. On the other hand, the main disadvantage is the high

renal dependence of its clearance. The drug is indicated for prophylaxis of thromboembolic disease in patients undergoing major orthopedic

surgery or other major surgery and in non-surgical patients with high risk of thromboembolic complications. Fondaparinux

is also an alternative therapy for patient with pulmonary embolism, deep venous thrombosis and acute coronary syndromes in specific

clinical settings. Hence, it is also a good option for patients having heparin induced thrombocytopenia where both LMWH and UFH are

contra-indicated.

Keywords: fondaparinux, parenteral anticoagulants, deep vein thrombosis, acute coronary syndrome.

Published: July 15, 2009  Show citation